Although we were not allowed to get enough tissues to isolate hADSC from MSL patients, our findings suggest that the RhoA/ROCK1/ERK1/2 signaling pathway is a potential therapeutic target for the development of drugs that prevent or treat MSL or obesity patients. The gene discussed is MAPK3; the disease is multiple symmetric lipomatosis.